BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...
BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...
The designation is granted for the treatment of advanced or metastatic CLDN1+ squamous cancers irrespective of the organ of origin BASEL, Switzerland, November 18, 2024--(BUSINESS WIRE)--Alentis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback